Wirkstoffe & Arzneimittelsicherheit

Wechselwirkungen · Kaletra

Kaletra 200 mg/50 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 61

HOS-109024 · Präparat HOS-093083

Thyroid hormone replacement therapy Levothyroxine Post-marketing cases have been Thyroid-stimulating hormone (TSH) reported indicating a potential should be monitored in patients interaction between ritonavir treated with levothyroxine at least the containing products and first month after starting and/or levothyroxine. ending lopinavir/ritonavir treatment. Vasodilating agents Bosentan Lopinavir - ritonavir: Caution should be exercised in Lopinavir/ritonavir plasma administering Kaletra with bosentan. concentrations may decrease due When Kaletra is administered to CYP3A4 induction by concomitantly with bosentan, the bosentan. efficacy of the HIV therapy should be monitored and patients should be Bosentan: closely observed for bosentan AUC: ↑ 5-fold toxicity, especially during the first Cmax: ↑ 6-fold week of co-administration. Initially, bosentan Cmin: ↑ by approximately 48-fold. Due to CYP3A4 inhibition by lopinavir/ritonavir. Riociguat Serum concentrations may be The co-administration of riociguat increased due to CYP3A and P-gp with Kaletra is not recommended inhibition by lopinavir/ritonavir. (see section 4.4 and refer to riociguat SmPC). Other medicinal products Based on known metabolic profiles, clinically significant interactions are not expected between Kaletra and dapsone, trimethoprim/sulfamethoxazole, azithromycin or fluconazole.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sulfamethoxazole (HOS-084533) riociguat (HOS-086293) trimethoprim (HOS-085184) azithromycin (HOS-088112) fluconazole (HOS-087945) bosentan (HOS-086291) dapsone (HOS-088141) levothyroxine (HOS-086339)